Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma (Q39242233)

10 September 2017

Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma (English)

1 reference

10 September 2017

9

Ola Myklebost

1 reference

10 September 2017

Hege O Ohnstad

1

1 reference

10 September 2017

Russell Castro

2

1 reference

10 September 2017

Jinchang Sun

3

1 reference

10 September 2017

Karen-Marie Heintz

4

1 reference

10 September 2017

Lyubomir T Vassilev

5

1 reference

10 September 2017

Bodil Bjerkehagen

6

1 reference

10 September 2017

Stine H Kresse

7

1 reference

10 September 2017

Leonardo A Meza-Zepeda

8

1 reference

10 September 2017

language of work or name

English

0 references

publication date

16 November 2012

1 reference

10 September 2017

1 reference

10 September 2017

119

1 reference

10 September 2017

5

1 reference

10 September 2017

1013-1022

1 reference

10 September 2017

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Functions of the MDM2 oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

The MDM2 gene amplification database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

p53 polymorphisms: cancer implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

The codon 72 polymorphic variants of p53 have markedly different apoptotic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Two polymorphic variants of wild-type p53 differ biochemically and biologically

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Amplification of a gene encoding a p53-associated protein in human sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

A common polymorphism acts as an intragenic modifier of mutant p53 behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

7 January 2021

MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

7 January 2021

Is p53 polymorphism maintained by natural selection?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

7 January 2021

SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

7 January 2021

Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

7 January 2021

Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27837

7 January 2021

Identifiers

DOI

10.1002/CNCR.27837

1 reference

release_gbw3ocs4hfc4rlqylldcfewck4

10 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gbw3ocs4hfc4rlqylldcfewck4

24 November 2022

mapped directly with Wikidata item

1 reference